혈액내과 임상약사의 처방중재 활동 평가 = Evaluation of Clinical Pharmacist’s Interventions in Hematology

다국어 초록 (Multilingual Abstract)

Background : The significance of the pharmacist’s clinical role has been demonstrated through several studies, and its importance is further emphasized through medication therapy management in hematology. Although many hematology clinical pharmacists operate in various hospitals domestically and abroad, few studies have evaluated the value of the pharmacists’ prescription interventions. The only domestic study to analyze the prescription interventions by hematology clinical pharmacists was published in 2014. However, it does not use the current revised classification criteria. Thus, the purpose of this study was to re-examine the prescription interventions of hematology clinical pharmacists in the current clinical context.
Methods : The details of drug-related interventions were studied among patients admitted to a hospital’s hematology department July 2018-June 2019. The intervention cases were analyzed using the Pharmaceutical Care Network Europe (PCNE) version 9.0 criteria to determine the type of prescription interventions, the cause of drug-related problems, and if accepted. The Overhage criteria was applied to assess the significance of the interventions.
Results : A total of 394 cases of drug prescription intervention were identified for analysis. The study results revealed that the most prescription-mediated drugs were antiemetics (15.3%), followed by antibiotics (13.4%), and antifungal agents (10.2%). According to the PCNE, the most frequently observed prescription intervention was “Effect of drug treatment not optimal (36.3%)”. The most frequent cause for the prescription intervention was “No or incomplete drug treatment in spite of existing indication (31.3%)”. The prescription intervention was accepted in 68.5%, of which 94.7% had clinical significance.
Conclusion : This study confirmed that the clinical pharmacist in hematology conducts various and clinically significant interventions which optimize patient care. Thus, the results affirmed the positive/health-promoting role of the clinical pharmacist and we expect such results to serve as a basis for increasing in awareness of the role and importance of the clinical pharmacist.

참고문헌 (Reference)

1 정채린, "혈액종양환자에서의 약물관련문제 분석과 이에 대한 임상약사의 중재 가치 평가" 서울대학교 대학원 2014

2 정정원, "외과계 중환자실 약사의 처방중재효과 평가" 한국병원약사회 31 (31): 908-918, 2014

3 유소현, "약사에 의한 항암처방 중재 분석 및 처방 오류 개선 효과" 한국병원약사회 29 (29): 131-138, 2012

4 김효정, "내과계 중환자실 팀활동을 통한 약사의 처방중재 활동 평가" 한국병원약사회 35 (35): 319-330, 2018

5 EUROPE, Pharmaceutical Care Network, "The PCNE Classification V 9.02019"

6 Carreras E, "The EBMT Handbook. Hematopoietic stem cell transplantation and cellular therapies" Springer 2019

7 Gates PJ, "Preventable Adverse Drug Events Among Inpatients : A Systematic Review" 142 (142): 87-, 2018

8 Overhage JM, "Practical, reliable, comprehensive method for characterizing pharmacists’ clinical activities" 56 (56): 2444-2450, 1999

9 Kim MG, "Network analysis of drug-related problems in hospitalized patients with hematologic malignancies" 26 (26): 2737-2742, 2018

10 Fernández-Llamazares CM, "Impact of clinical pharmacist interventions in reducing paediatric prescribing errors" 97 (97): 564-568, 2012

11 Liekweg A, "From oncology pharmacy to pharmaceutical care : new contributions to multidisciplinary cancer care" 12 (12): 73-79, 2004

12 Knez L, "Evaluation of clinical interventions made by pharmacists in cancer services" 280 (280): 277-280, 2008

13 Blower P, "Drug–drug interactions in oncology : why are they important and can they be minimized" 55 (55): 117-142, 2005

14 Chan A, "Clinical pharmacy services and research for lymphoma patients at a cancer center" 19 (19): 24-30, 2013